NO20075074L - Kinazolinon T-type-kalsiumkanalantagonister - Google Patents
Kinazolinon T-type-kalsiumkanalantagonisterInfo
- Publication number
- NO20075074L NO20075074L NO20075074A NO20075074A NO20075074L NO 20075074 L NO20075074 L NO 20075074L NO 20075074 A NO20075074 A NO 20075074A NO 20075074 A NO20075074 A NO 20075074A NO 20075074 L NO20075074 L NO 20075074L
- Authority
- NO
- Norway
- Prior art keywords
- type calcium
- kinazolinone
- calcium channel
- channel antagonists
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- C07D239/82—Oxygen atoms with an aryl radical attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65995405P | 2005-03-09 | 2005-03-09 | |
| PCT/US2006/008177 WO2006098969A2 (en) | 2005-03-09 | 2006-03-08 | Quinazolinone t-type calcium channel antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20075074L true NO20075074L (no) | 2007-11-30 |
Family
ID=36992208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20075074A NO20075074L (no) | 2005-03-09 | 2007-10-08 | Kinazolinon T-type-kalsiumkanalantagonister |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7745452B2 (de) |
| EP (1) | EP1858520B1 (de) |
| JP (1) | JP2008533020A (de) |
| KR (1) | KR20070110081A (de) |
| CN (1) | CN101137380A (de) |
| AT (1) | ATE527243T1 (de) |
| AU (1) | AU2006223469A1 (de) |
| BR (1) | BRPI0608343A2 (de) |
| CA (1) | CA2600868A1 (de) |
| IL (1) | IL185391A0 (de) |
| MX (1) | MX2007010965A (de) |
| NO (1) | NO20075074L (de) |
| RU (1) | RU2007137266A (de) |
| WO (1) | WO2006098969A2 (de) |
| ZA (1) | ZA200706740B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006223469A1 (en) * | 2005-03-09 | 2006-09-21 | Merck Sharp & Dohme Corp. | Quinazolinone T-type calcium channel antagonists |
| WO2008138126A1 (en) * | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
| CA2692783A1 (en) * | 2007-07-10 | 2009-01-15 | Merck Sharp & Dohme Corp. | Quinazolinone t-type calcium channel antagonists |
| CA2701203A1 (en) | 2007-10-04 | 2009-04-09 | Merck Sharp & Dohme Corp. | N-substituted oxindoline derivatives as calcium channel blockers |
| AU2008308092B2 (en) * | 2007-10-05 | 2013-07-11 | Msd K.K. | Benzoxazinone derivative |
| AU2008363295B2 (en) | 2008-10-20 | 2015-05-07 | Forschungsverbund Berlin E.V. | Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists |
| FR2937552B1 (fr) * | 2008-10-27 | 2011-05-06 | Biocodex | Composition pharmaceutique destinee a la prevention ou au traitement du syndrome de sevrage alcoolique |
| EP2563777A4 (de) | 2010-04-08 | 2013-09-04 | Us Health | Inverse agonisten und neutrale agonisten für den tsh-rezeptor |
| EP2578573A4 (de) * | 2010-05-24 | 2014-08-06 | Toa Eiyo Ltd | Kondensiertes imidazolderivat |
| RU2650107C2 (ru) * | 2012-09-26 | 2018-04-09 | Мерк Патент Гмбх | Производные хиназолинона в качестве ингибиторов parp |
| WO2015111004A2 (en) * | 2014-01-24 | 2015-07-30 | Discovery Intermediates Private Limited | Improved process for the preparation of chlorophenyl trifluoroethanone |
| US9145388B2 (en) | 2014-02-19 | 2015-09-29 | King Fahd University Of Petroleum And Minerals | 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones |
| ES2715050T3 (es) | 2014-05-28 | 2019-05-31 | Toa Eiyo Ltd | Derivados de tropano sustituidos |
| DK3364993T3 (da) | 2015-10-22 | 2023-01-09 | Cavion Inc | Fremgangsmåder til behandling af angelman syndrom |
| WO2018152317A1 (en) | 2017-02-15 | 2018-08-23 | Cavion, Inc. | Calcium channel inhibitors |
| CN106749045B (zh) * | 2017-03-03 | 2020-02-14 | 上海交通大学 | 一种d-氨基酸氧化酶抑制剂及其制法和应用 |
| MX2019012818A (es) * | 2017-04-26 | 2020-07-14 | Cavion Inc | Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos. |
| WO2020072773A1 (en) | 2018-10-03 | 2020-04-09 | Cavion, Inc. | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
| JP2022540253A (ja) | 2019-07-11 | 2022-09-14 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｔ型カルシウムチャネル調節因子の製剤およびその使用方法 |
| CN118434722A (zh) | 2021-10-20 | 2024-08-02 | 英矽智能科技知识产权有限公司 | 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途 |
| WO2025255502A1 (en) | 2024-06-07 | 2025-12-11 | Cavion, Inc. | PYRIDYL AMIDE Cav3 CHANNEL MODULATORS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL102764A0 (en) | 1991-08-16 | 1993-01-31 | Merck & Co Inc | Quinazoline derivatives,and pharmaceutical compositions containing them |
| AU2436792A (en) | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| DE4320347A1 (de) * | 1993-06-19 | 1994-12-22 | Boehringer Mannheim Gmbh | Quinazolin-Derivate und diese enthaltende Arzneimittel |
| EP1066039A4 (de) * | 1998-03-02 | 2003-02-26 | Cocensys Inc | Substituierte quinazoline und deren analoge und verwendungen |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| JP3691341B2 (ja) * | 2000-05-16 | 2005-09-07 | 日新製鋼株式会社 | 精密打抜き性に優れたオーステナイト系ステンレス鋼板 |
| US20060003985A1 (en) | 2002-10-17 | 2006-01-05 | Renger John J | Enhancement of sleep with t-type calcium channel antagonists |
| CN1856310A (zh) * | 2003-09-23 | 2006-11-01 | 默克公司 | 喹唑啉钾通道抑制剂 |
| US20070010537A1 (en) | 2004-08-20 | 2007-01-11 | Kazumasa Hamamura | Fused pyramidine derivative and use thereof |
| AU2006223469A1 (en) * | 2005-03-09 | 2006-09-21 | Merck Sharp & Dohme Corp. | Quinazolinone T-type calcium channel antagonists |
| CA2573525A1 (en) * | 2006-01-12 | 2007-07-12 | Hitachi, Ltd. | Materials location system and selecting method of materials receiving locations |
-
2006
- 2006-03-08 AU AU2006223469A patent/AU2006223469A1/en not_active Abandoned
- 2006-03-08 US US11/886,053 patent/US7745452B2/en active Active
- 2006-03-08 CA CA002600868A patent/CA2600868A1/en not_active Abandoned
- 2006-03-08 EP EP06737357A patent/EP1858520B1/de active Active
- 2006-03-08 RU RU2007137266/04A patent/RU2007137266A/ru not_active Application Discontinuation
- 2006-03-08 MX MX2007010965A patent/MX2007010965A/es unknown
- 2006-03-08 KR KR1020077020586A patent/KR20070110081A/ko not_active Withdrawn
- 2006-03-08 WO PCT/US2006/008177 patent/WO2006098969A2/en not_active Ceased
- 2006-03-08 JP JP2008500859A patent/JP2008533020A/ja not_active Withdrawn
- 2006-03-08 AT AT06737357T patent/ATE527243T1/de not_active IP Right Cessation
- 2006-03-08 BR BRPI0608343A patent/BRPI0608343A2/pt not_active IP Right Cessation
- 2006-03-08 CN CNA2006800072450A patent/CN101137380A/zh active Pending
-
2007
- 2007-08-14 ZA ZA200706740A patent/ZA200706740B/xx unknown
- 2007-08-20 IL IL185391A patent/IL185391A0/en unknown
- 2007-10-08 NO NO20075074A patent/NO20075074L/no not_active Application Discontinuation
-
2010
- 2010-06-28 US US12/824,702 patent/US20100261741A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7745452B2 (en) | 2010-06-29 |
| RU2007137266A (ru) | 2009-04-20 |
| BRPI0608343A2 (pt) | 2016-10-04 |
| ATE527243T1 (de) | 2011-10-15 |
| CN101137380A (zh) | 2008-03-05 |
| ZA200706740B (en) | 2008-09-25 |
| WO2006098969A2 (en) | 2006-09-21 |
| KR20070110081A (ko) | 2007-11-15 |
| WO2006098969A3 (en) | 2007-03-01 |
| JP2008533020A (ja) | 2008-08-21 |
| AU2006223469A1 (en) | 2006-09-21 |
| EP1858520A4 (de) | 2010-02-10 |
| US20080167329A1 (en) | 2008-07-10 |
| CA2600868A1 (en) | 2006-09-21 |
| MX2007010965A (es) | 2007-09-19 |
| IL185391A0 (en) | 2008-02-09 |
| EP1858520B1 (de) | 2011-10-05 |
| US20100261741A1 (en) | 2010-10-14 |
| EP1858520A2 (de) | 2007-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075074L (no) | Kinazolinon T-type-kalsiumkanalantagonister | |
| MX2010004530A (es) | Antagonistas de los canales de calcio tipo t de heterociclo fenil amida. | |
| WO2007120729A3 (en) | Pyridyl amide t-type calcium channel antagonists | |
| TW200714604A (en) | Substituted heterocycles and the uses thereof | |
| WO2007002884A3 (en) | 4-fluoro-piperidine t-type calcium channel antagonists | |
| DE602007008434D1 (de) | Rezeptoren | |
| EA201690265A2 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| DE602004013563D1 (de) | Rantagonisten | |
| EP1606286A4 (de) | Benzodiazepinspirohydantoine als cgrp-rezeptorantagonisten | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| TW200716546A (en) | Oxindole compounds and their uses as therapeutic agents | |
| CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| WO2008008551A3 (en) | 2-substituted proline bis-amide orexin receptor antagonists | |
| EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
| TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| ATE516803T1 (de) | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten | |
| MA31451B1 (fr) | Antagonistes des recepteurs de l'orexine de pyridyl piperidine. | |
| MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
| MX2009010127A (es) | Compuestos utiles como inhibidores de janus cinasas. | |
| MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| ATE493412T1 (de) | Spirohydantoin-aryl-cgrp-rezeptorantagonisten | |
| TW200724543A (en) | Heterocyclic compounds and their uses as therapeutic agents | |
| WO2007002361A3 (en) | 3-fluoro-piperidine t-type calcium channel antagonists | |
| EA200801343A1 (ru) | Иммуноглобулины, направленные против nogo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |